Therapeutic options for Acinetobacter baumannii infections: an update

被引:73
作者
Vila, Jordi [1 ,2 ]
Pachon, Jeronimo [3 ]
机构
[1] Univ Barcelona, Hosp Clin, Dept Clin Microbiol, Sch Med, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin, CRESIB, Barcelona Ctr Int Hlth Res, E-08036 Barcelona, Spain
[3] Univ Seville, CSIC, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, Seville, Spain
关键词
Acinetobacter baumannii; antimicrobial resistance; infections; treatment; VENTILATOR-ASSOCIATED PNEUMONIA; IN-VITRO ACTIVITY; CRITICALLY-ILL PATIENTS; MULTIDRUG-RESISTANT STRAINS; BETA-LACTAMASE INHIBITORS; COLISTIN RESISTANCE; ANTIMICROBIAL RESISTANCE; NOSOCOMIAL INFECTIONS; CLINICAL IMPACT; PHOSPHOETHANOLAMINE MODIFICATION;
D O I
10.1517/14656566.2012.729820
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Although the clinical importance of Acinetobacter pittii and Acinetobacter nosocomialis has increased in the nosocomial setting in the last decade, infections caused by Acinetobacter baumannii still have the highest clinical relevance. The most important features of this latter species are the ability to persist in the hospital environment and the multi-drug, extended-drug or pandrug resistance they may present which compromises the treatment of infections caused by this microorganism. Areas covered: In the present review, the authors describe the molecular bases of the acquisition of resistant mechanisms as well as different current and potential future strategies to treat infections caused by multi-drug resistant A. baumannii. Expert opinion: With the increase in resistance to carbapenems, colistin has been extensively used, however some data suggest that the doses recommended are insufficient before a steady state is reached, suggesting that the administration of a loading dose on initiation of treatment may be beneficial. Combinations of antibacterial agents such as impenem plus sulbactam or imipenem plus colistin have been successfully used to treat VAP. Nonetheless, future alternatives for treating A. baumannii infections should be explored.
引用
收藏
页码:2319 / 2336
页数:18
相关论文
共 148 条
[1]   Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System [J].
Adams, Mark D. ;
Nickel, Gabrielle C. ;
Bajaksouzian, Saralee ;
Lavender, Heather ;
Murthy, A. Rekha ;
Jacobs, Michael R. ;
Bonomo, Robert A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (09) :3628-3634
[2]   Emergence of Tigecycline and Colistin Resistance in Acinetobacter Species Isolated from Patients in Kuwait Hospitals [J].
Al-Sweih, N. A. ;
Al-Hubail, M. A. ;
Rotimi, V. O. .
JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) :13-16
[3]   The pmrCAB Operon Mediates Polymyxin Resistance in Acinetobacter baumannii ATCC 17978 and Clinical Isolates through Phosphoethanolamine Modification of Lipid A [J].
Arroyo, Luis A. ;
Herrera, Carmen M. ;
Fernandez, Lucia ;
Hankins, Jessica V. ;
Trent, M. Stephen ;
Hancock, Robert E. W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (08) :3743-3751
[4]   Pharmacodynamic Assessment of Amoxicillin-Sulbactam Against Acinetobacter baumannii: Searching the Optimal Dose and Infusion Time Through a Human ex-vivo Model [J].
Bantar, Carlos ;
Fernandez Canigia, Liliana ;
Alejandra Berger, Maria ;
Soutric, Jorge L. ;
Arenoso, Hector J. .
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2009, 13 (05) :348-352
[5]   Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections [J].
Bassetti, M. ;
Repetto, E. ;
Righi, E. ;
Boni, S. ;
Diverio, M. ;
Molinari, M. P. ;
Mussap, M. ;
Artioli, S. ;
Ansaldi, F. ;
Durando, P. ;
Orengo, G. ;
Pallavicini, F. Bobbio ;
Viscoli, C. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) :417-420
[6]   Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System [J].
Beceiro, Alejandro ;
Llobet, Enrique ;
Aranda, Jesus ;
Antonio Bengoechea, Jose ;
Doumith, Michel ;
Hornsey, Michael ;
Dhanji, Hiran ;
Chart, Henrik ;
Bou, German ;
Livermore, David M. ;
Woodford, Neil .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) :3370-3379
[7]   Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia [J].
Bernabeu-Wittel, M ;
Pichardo, C ;
García-Curiel, A ;
Pachón-Ibáñez, ME ;
Ibáñez-Martínez, J ;
Jiménez-Mejías, ME ;
Pachón, J .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (04) :319-325
[8]   Antimicrobial Susceptibility Among Gram-Negative Isolates Collected From Intensive Care Units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa Between 2004 and 2009 as Part of the Tigecycline Evaluation and Surveillance Trial [J].
Bertrand, Xavier ;
Dowzicky, Michael J. .
CLINICAL THERAPEUTICS, 2012, 34 (01) :124-137
[9]   Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers.: Second multicenter study [J].
Betriu, Carmen ;
Rodriguez-Avial, Iciar ;
Gomez, Maria ;
Culebras, Esther ;
Lopez, Fatima ;
Alvarez, Juan ;
Picazo, Juan J. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 56 (04) :437-444
[10]   Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia [J].
Betrosian, Alex P. ;
Frantzeskaki, Frantzeska ;
Xanthaki, Anna ;
Douzinas, Emmanuel E. .
JOURNAL OF INFECTION, 2008, 56 (06) :432-436